Pharmaceutical Executive Daily: Parabilis Medicines Prices Record-Breaking $670 Million IPO
Jun 10, 07:06 PM
Share
Subscribe
In today's Pharmaceutical Executive Daily, Parabilis Medicines prices a record-breaking $670 million IPO, Swedish biotech AlzeCure Pharma enters a collaboration and out-licensing agreement with Eli Lilly for its Alzheimer's candidate, and FDA approves an every-eight-week maintenance dosing regimen for Eli Lilly's Ebglyss.